A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
The study consisted of:
- A 30-day screening phase prior to Day 1
- Day 1 registration and pre-treatment paracentesis
- Aflibercept administration within 1-day of registration
- Two-week study treatment cycles (for efficacy data, the cut-off date was 6 months
post-registration
- A 60-day post-treatment follow-up phase
During the study, participants were treated with Aflibercept study treatment through the
duration of the study unless they met one the following criteria for discontinuation:
- Participant (or legal representative) chose to withdraw from treatment
- The investigator or sponsor thought that continuation of the study would be detrimental
to the participants well-being
- Participant had intercurrent illness that prevented further administration of
investigational product (IP)
- Participant had more than 2 IP dose reductions
- Participant had unacceptable adverse events (AEs)
- Participant had arterial thromboembolic events, including cerebrovascular accidents,
myocardial infarctions, transient ischemic attacks, new onset angina, or worsening of
preexisting angina
- Participant required surgical intervention for intestinal obstruction or
gastrointestinal perforation
Participants that met the following criteria were eligible.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of Participants With a Repeat Paracentesis Response (RPR)
RPR was defined as at least a two-fold increase in the time to repeat paracentesis (TRP) as compared to the average duration of the 2 intervals between the 3 most recent paracenteses prior to study registration (ie, the baseline interval of paracentesis). Percentage of participants with a repeat paracentesis response were the number of participants with RPR / number of total participants * 100.
up to 2 years post-registration
No
ICD
Study Director
Sanofi
United States: Food and Drug Administration
ARD6772
NCT00396591
October 2006
November 2008
Name | Location |
---|---|
Sanofi-Aventis Administrative Office | Bridgewater, New Jersey 08807 |